Celsion Scores Patent for Delivery System

Celsion received U.S. patent protection covering its lung-specific delivery system, TheraSilence.

The patent covers TheraSilence compositions and delivery forms in a range of therapeutic RNA entities.

“Our strategy is to seek to maximize the value of this platform in the near-term by pursuing collaborations and development agreements, while focusing internal development efforts on our two clinical stage candidates, ThermoDox and GEN-1, our DNA-based immunotherapy for the localized treatment of ovarian cancer,” Michael Targundo, chairman, president and CEO of Celsion, said in a prepared statement. — Anisa Jibrell